Clinical Trial Update: A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks [Phase 2]

View source ↗

Summary

This Phase 2 trial assesses vonoprazan 20 mg versus placebo in adults with eosinophilic esophagitis, evaluating outcomes after 12 weeks and up to 24 weeks; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Esophagitis

Drugs mentioned

• Vonoprazan (vonoprazan)

Snippet

Sponsor: Phathom Pharmaceuticals, Inc. | Conditions: Eosinophilic Esophagitis | Phase 2 | Status: RECRUITING